The effect of ethane 1 hydroxy 1,1 diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stone formers

W. G. Robertson, Munro Peacock, R. W. Marshall, F. Knowles

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The volume, size and type of calcium oxalate crystals excreted in the urine of a group of patients with recurrent 'idiopathic' stones were studied on a controlled basal diet, after an oral supplement of sodium oxalate and after oral administration of ethane 1 hydroxy 1,1 diphosphonate (EHDP) for 4 wk. Before administration of EHDP the stone formers passed the large crystals and aggregates of calcium oxalate dihydrate characteristic of recurrent calcium oxalate stone formers. For the same level of urine saturation and crystalluria EHDP caused a significant reduction in the proportion of large crystals and aggregates excreted. Studies by light microscopy confirmed that EHDP caused a striking change in the size and habit of calcium oxalate crystals in some but not all of the urine samples examined. The decrease in average crystal size during the administration of EHDP was attributed to the observed increase in the ability of urine to inhibit the growth and aggregation of calcium oxalate crystals as measured by a growth system in vitro. The possible use of EHDP as a therapeutic agent in the treatment of calcium oxalate stone formation is discussed.

Original languageEnglish (US)
Pages (from-to)13-22
Number of pages10
JournalClinical Science and Molecular Medicine
Volume47
Issue number1
StatePublished - 1974
Externally publishedYes

Fingerprint

Calcium Oxalate
Ethane
Diphosphonates
Kidney
Urine
Oxalic Acid
Aptitude
Growth
Habits
Oral Administration
Microscopy
Diet
Light
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of ethane 1 hydroxy 1,1 diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stone formers. / Robertson, W. G.; Peacock, Munro; Marshall, R. W.; Knowles, F.

In: Clinical Science and Molecular Medicine, Vol. 47, No. 1, 1974, p. 13-22.

Research output: Contribution to journalArticle

@article{6ad3c93b789a40c0b25f72fb742fc36b,
title = "The effect of ethane 1 hydroxy 1,1 diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stone formers",
abstract = "The volume, size and type of calcium oxalate crystals excreted in the urine of a group of patients with recurrent 'idiopathic' stones were studied on a controlled basal diet, after an oral supplement of sodium oxalate and after oral administration of ethane 1 hydroxy 1,1 diphosphonate (EHDP) for 4 wk. Before administration of EHDP the stone formers passed the large crystals and aggregates of calcium oxalate dihydrate characteristic of recurrent calcium oxalate stone formers. For the same level of urine saturation and crystalluria EHDP caused a significant reduction in the proportion of large crystals and aggregates excreted. Studies by light microscopy confirmed that EHDP caused a striking change in the size and habit of calcium oxalate crystals in some but not all of the urine samples examined. The decrease in average crystal size during the administration of EHDP was attributed to the observed increase in the ability of urine to inhibit the growth and aggregation of calcium oxalate crystals as measured by a growth system in vitro. The possible use of EHDP as a therapeutic agent in the treatment of calcium oxalate stone formation is discussed.",
author = "Robertson, {W. G.} and Munro Peacock and Marshall, {R. W.} and F. Knowles",
year = "1974",
language = "English (US)",
volume = "47",
pages = "13--22",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - The effect of ethane 1 hydroxy 1,1 diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stone formers

AU - Robertson, W. G.

AU - Peacock, Munro

AU - Marshall, R. W.

AU - Knowles, F.

PY - 1974

Y1 - 1974

N2 - The volume, size and type of calcium oxalate crystals excreted in the urine of a group of patients with recurrent 'idiopathic' stones were studied on a controlled basal diet, after an oral supplement of sodium oxalate and after oral administration of ethane 1 hydroxy 1,1 diphosphonate (EHDP) for 4 wk. Before administration of EHDP the stone formers passed the large crystals and aggregates of calcium oxalate dihydrate characteristic of recurrent calcium oxalate stone formers. For the same level of urine saturation and crystalluria EHDP caused a significant reduction in the proportion of large crystals and aggregates excreted. Studies by light microscopy confirmed that EHDP caused a striking change in the size and habit of calcium oxalate crystals in some but not all of the urine samples examined. The decrease in average crystal size during the administration of EHDP was attributed to the observed increase in the ability of urine to inhibit the growth and aggregation of calcium oxalate crystals as measured by a growth system in vitro. The possible use of EHDP as a therapeutic agent in the treatment of calcium oxalate stone formation is discussed.

AB - The volume, size and type of calcium oxalate crystals excreted in the urine of a group of patients with recurrent 'idiopathic' stones were studied on a controlled basal diet, after an oral supplement of sodium oxalate and after oral administration of ethane 1 hydroxy 1,1 diphosphonate (EHDP) for 4 wk. Before administration of EHDP the stone formers passed the large crystals and aggregates of calcium oxalate dihydrate characteristic of recurrent calcium oxalate stone formers. For the same level of urine saturation and crystalluria EHDP caused a significant reduction in the proportion of large crystals and aggregates excreted. Studies by light microscopy confirmed that EHDP caused a striking change in the size and habit of calcium oxalate crystals in some but not all of the urine samples examined. The decrease in average crystal size during the administration of EHDP was attributed to the observed increase in the ability of urine to inhibit the growth and aggregation of calcium oxalate crystals as measured by a growth system in vitro. The possible use of EHDP as a therapeutic agent in the treatment of calcium oxalate stone formation is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0016195211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016195211&partnerID=8YFLogxK

M3 - Article

C2 - 4277691

AN - SCOPUS:0016195211

VL - 47

SP - 13

EP - 22

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 1

ER -